Breast cancer in males

Unidad de Patología Mamaria, Servicio de Cirugía General y del Aparato Digestivo, Hospital Universitario Virgen del Rocío, Sevilla, España.
Cirugia y cirujanos (Impact Factor: 0.18). 07/2011; 79(4):296-8.
Source: PubMed


Male breast cancer has a very low incidence (<1%). It has traditionally been considered to have a poorer prognosis than breast cancer in females due to delayed diagnosis as a cause of decreased survival. Our goal is to analyze our series and to identify factors influencing survival.
We conducted a retrospective study from 1997-2008 (n = 32). Inclusion criteria were male gender and histological confirmation of breast cancer. We analyzed epidemiological data (age and personal and family history), tumors (size, grade of differentiation, histological type, location, TNM stage, receptors), therapeutic regimen (surgical technique, adjuvant therapy) and survival (relapse, followup, death).
Male breast cancer represents 0.9% of all breast cancers treated in our center. The average age of our patients was 66.84 years. Only 9.3% demonstrated gynecomastia as a presenting complaint. Histologically, 90% were infiltrating ductal type; 59.25% were diagnosed in early stages (I-II) compared to 40.74% in stages III-IV. Aggressive surgical techniques are still performed, compared to conservative techniques (74.19% vs. 19.36%). With a median follow-up of 52.82 months, the mortality rate was 16%. Existence of distant metastasis has been the only statistically significant factor in survival.
The percentage of cases of male breast cancer is very low compared to breast cancer in females. Limited studies in the literature make gender-specific findings difficult. A low percentage of conservative surgical procedures are performed, even though this has increased considerably in recent years. The existence of distant metastasis was the main determinant of survival.

Download full-text


Available from: Luis Tallón-Aguilar, Dec 14, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate efficacy of laser lipolysis in the treatment of gynecomastia to correct breast volume, flaccidity and excess skin without its excision. Prospectively, 32 patients with gynecomastia under tumescent anaesthesia and sedation underwent laser lipolysis with 980nm diode laser, 15W continuous emission and 8 to 12 kJ energy per breast. Externally cold air was used to protect the skin. No drainages were used but a compressive bandage. Patients evaluated results on a VAS scale. Two doctors evaluated results comparing before and 6 month after photographs and also measured the areola and chest diameter. Twenty three patients considered results as Very Good, 7 Good and 2 Fair Cutaneous retraction of the areola was noticeable one month after the surgery and was maximum 6 months after. Evaluation by doctors was 26 Very Good, 5 Good and 1 Fair. There were no burns, ischemia or lesions in areolas or nipples. Laser assisted liposuction is a simple and efficacious technique, barely traumatic and permits a rapid reincorporation to normal activitie.
    Preview · Article · Feb 2013 · Revista do Colégio Brasileiro de Cirurgiões
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Male breast cancer accounts for less than 1% of all cancer in men and only around 1% of all diagnosed breast cancer. Despite a significant raise in the last 25 years, it still remains a rare disease. Materials and methods: We conducted a retrospective study from 2004-2011 with 21 male breast cancer patients. We aimed to analyze the epidemiologic data (age, personal and family history), tumor characteristics (size, histological type, location, TNM stage, receptors), surgery, adjuvant chemotherapy and radiation therapy, hormonal therapy and survival (relapse, follow up, death) who reffered to our center with breast cancer. Results: The median age was 49.2±14.2 years (range 30-83 years). A family history of breast cancer was noted in four cases. The main clinical complaint was a retroareolar mass in 85.7%of patients (n=18). Histologically, 85.7% (n=18)were invasive ductal carcinoma and 4.7% (n=1) had ductal carcinoma in situ and 9.4% (n=2) had mixed histology including invasive medullary and ductal carcinoma. Hormonal therapy was delivered to 16 cases (76.1%) due to ER or PR positivity. During median follow up of 30 months (3-84 month), distant metastases were evident in 4 cases (19%). During the follow-up period, only one patient died due to metastatic disease. The mean time to recurrence detection was 30 months. Conclusions: The percentage of cases of male breast cancer is very low compared to breast cancer in females, explaining why very few investigations have been conducted in Iran. Limited coverage in the literature make gender-specific findings difficult so future research of this entity involving multi-institutional cooperation and longer follow up is essential to provide new insights about the biological and clinical factors of this rare cancer.
    Full-text · Article · Dec 2013 · Asian Pacific journal of cancer prevention: APJCP
  • [Show abstract] [Hide abstract]
    ABSTRACT: Male breast cancer occurs very rare accounts for about 0.2-1% of all male cancers. The ratio of the breast cancer incidence in male and female patients is approximately 1:100. Median age of breast cancer initiation in males is 67 – 71 years of age, that is 5 – 10 years later than that in women. The main risk factors of male breast cancer include hormonal abnormalities, particularly hyperestrogenia, congenital factors and radiation. Male breast carcinoma demonstrates strong estrogen and progesterone expression, as determined by the IHC staining: 91 and 76%, respectively. These numbers are much higher than those in female patients. Hyperexpression and amplification of Her-2/neu gene is also an essential feature for male breast carcinoma. There are very limited data available on metastatic progression of male breast carcinoma. One study evaluated 127 cases of male breast cancer, and distant metastatic affection was seen in 32% cases, among them distant metastases were most frequently situated in bones. There are also reports about metastases in lungs, liver and skin, but their incidence is so low, that these reports are not analyzed and described in details by their authors. There are some reports of unusual metastatic locations. For instance, a metastatic tumor growth in mandibular joint was reported in 73-year-old male patient with ductal breast cancer in March 2012. Earlier, in 2010, the same group described a metastasis in paranasal sinus. Here we report a very rare occurrence of a brain metastatic disease in a male breast carcinoma patient. Based on literary data we found only two previously published case reports of similar disease development. However, we believe that investigation of single cases of brain metastases in patients with male breast cancer and determination of characteristic features for such disease progression will allow us to find optimal strategies for application of various therapy options including chemotherapy and hormone-therapy in the treatment of this category of patients.
    No preview · Article · Jan 2014 · New Armenian Medical Journal
Show more